RxDoctor Payments Data

Diane Zuelke

Family · Morris, ILNPI 1093024200

Payments from drug & device makers

$407in general payments, 2019–2025

Across 12 payments — averaging $33.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$146
  • Edwards Lifesciences$79
  • Exact Sciences$49
  • Boston Scientific$48
  • Orexo US, Inc.$23
  • Takeda Pharmaceuticals U.S.A., Inc.$19
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$407100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$407 in reported general payments places this provider in the 55th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$135,361
Medicare patients
398
Services billed
1,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$52,656
EliquisApixaban75$49,316
JardianceEmpagliflozin31$44,859
TradjentaLinagliptin23$31,050
MounjaroTirzepatide27$27,760
JanuviaSitagliptin Phosphate26$15,182
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$15,048
MyrbetriqMirabegron20$14,645
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,469
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl40$8,467
Breo ElliptaFluticasone/Vilanterol11$7,658
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$7,491
XareltoRivaroxaban26$7,218
HumalogInsulin Lispro12$6,493
Spiriva HandihalerTiotropium Bromide13$6,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$146$75,90954 claims
PfizerEliquis$12$49,31675 claims
AstraZenecaBreztri Aerosphere, Brilinta, Symbicort$15$25,23466 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,941 family providers in Illinois.

Other family in Morris

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →